AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
benserazide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 314 | 322-35-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An inhibitor of DOPA DECARBOXYLASE that does not enter the central nervous system. It is often given with LEVODOPA in the treatment of parkinsonism to prevent the conversion of levodopa to dopamine in the periphery, thereby increasing the amount that reaches the central nervous system and reducing the required dose. It has no antiparkinson actions when given alone.
|
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 1 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 11.10 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| S (Water solubility) | 10 mg/mL | Bocci G, Oprea TI, Benet LZ |
| fu (Fraction unbound in plasma) | 0.73 % | Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K |
| BA (Bioavailability) | 59.20 % |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 1, 1990 | YEAR INTRODUCED |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug interaction | 78.76 | 56.45 | 35 | 445 | 276418 | 90351549 |
| Product prescribing error | 62.81 | 56.45 | 17 | 463 | 30128 | 90597839 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Drug interaction | 68.04 | 42.83 | 42 | 709 | 500141 | 110088407 |
| Product prescribing error | 61.60 | 42.83 | 20 | 731 | 51311 | 110537237 |
| General physical health deterioration | 48.43 | 42.83 | 32 | 719 | 425263 | 110163285 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| MeSH PA | D000978 | Antiparkinson Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D015259 | Dopamine Agents |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018726 | Anti-Dyskinesia Agents |
| CHEBI has role | CHEBI:48407 | antiparkinson drug |
| CHEBI has role | CHEBI:48560 | dopaminergic agent |
| CHEBI has role | CHEBI:59321 | EC 4.1.1.28 (aromatic-<small>L</small>-amino-acid decarboxylase) inhibitor |
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.67 | acidic |
| pKa2 | 11.55 | acidic |
| pKa3 | 12.19 | acidic |
| pKa4 | 13.97 | acidic |
| pKa5 | 6.88 | Basic |
| pKa6 | 3.1 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Aromatic-L-amino-acid decarboxylase | Enzyme | WOMBAT-PK | |||||||
| Estrogen receptor beta | Nuclear hormone receptor | IC50 | 5.52 | CHEMBL | |||||
| SUMO-activating enzyme | Enzyme | IC50 | 4.63 | CHEMBL | |||||
| Hexokinase-2 | Kinase | IC50 | 5.26 | CHEMBL | |||||
| Zinc finger protein mex-5 | Cytosolic other | EC50 | 6.95 | CHEMBL | |||||
| Cytoplasmic zinc-finger protein | Cytosolic other | EC50 | 4.43 | CHEMBL | |||||
| Genome polyprotein [Cleaved into: P1; Capsid protein VP0 | Enzyme | IC50 | 5.62 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D01653 | KEGG_DRUG |
| 14919-77-8 | SECONDARY_CAS_RN |
| 1374 | RXNORM |
| C0005014 | UMLSCUI |
| CHEBI:64187 | CHEBI |
| CHEMBL1096979 | ChEMBL_ID |
| CHEMBL1255778 | ChEMBL_ID |
| DB12783 | DRUGBANK_ID |
| D001545 | MESH_DESCRIPTOR_UI |
| 2327 | PUBCHEM_CID |
| 5150 | IUPHAR_LIGAND_ID |
| 3026 | INN_ID |
| 762OS3ZEJU | UNII |
| 003682 | NDDF |
| 003683 | NDDF |
| 391821005 | SNOMEDCT_US |
| 391822003 | SNOMEDCT_US |
| 420240007 | SNOMEDCT_US |
| 762OS3ZEJU | INXIGHT DRUGS |
Pharmaceutical products:
None